Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Tremfya®? (guselkumab) launched in the UK for treatment of moderate to severe psoriasis

Posted on: 23 Nov 17

High Wycombe, UK, 23rd November 2017 – Janssen has today announced that Tremfya® (guselkumab) is now available in the UK for adults with moderate to severe plaque psoriasis who are candidates for systemic therapy.[i] Psoriasis affects up to 3 percent of the UK population, an estimated 1.8 million people.[ii] It can cause great physical and psychological burden, with approximately one third of people with psoriasis experiencing depression and anxiety.[iii]


Guselkumab is the first biologic to selectively target interleukin (IL)-23, a key protein that initiates a specific immune inflammatory response.4-7 [iv],[v],[vi],[vii]


“We are delighted that guselkumab is now available for patients in the UK,” said Dr Frank Wiegand, Medical Director, Janssen UK. “At Janssen, we are committed to bringing innovative new therapies that help to improve the lives of those living with these debilitating diseases. The availability of guselkumab in the UK provides an innovative new option to help address the continued needs of people living with plaque psoriasis.”


The marketing authorisation and subsequent UK launch are based on data from three Phase 3 clinical studies. The VOYAGE 1 and 2 trials, which compared guselkumab with placebo and HUMIRA® (adalimumab), showed high levels of skin clearance after 16 weeks, with at least a 90 percent reduction in Psoriasis Area and Severity Index score (PASI 90) in 73.3% and 70.0% of patients receiving guselkumab, compared with 49.7% and 46.8% in patients receiving adalimumab, respectively (P<0.001).4,5


The NAVIGATE trial evaluated patients who did not achieve a response of cleared or minimal disease (Investigator’s Global Assessment [IGA] score of 0 or 1) by week 16 when treated with STELARA® (ustekinumab), and were then randomised to either switch to guselkumab or continue on ustekinumab.6 The guselkumab group had a significantly higher mean number of visits with patients achieving an IGA score of 0 or 1 and at least a 2-grade improvement from week 28 through week 40 (relative to week 16), compared to the ustekinumab group (1.5 vs 0.7; P<0.001).6


During the clinical development programme for guselkumab in psoriasis there were no clear signals of increased risk of malignancy, major cardiovascular events or serious infections, including tuberculosis and re-activation of latent tuberculosis.5,6,6 Guselkumab may increase risk of infection.[viii] Adverse events reported in at least 5% of guselkumab-treated patients during the first 16 weeks in the VOYAGE 1 and 2 trials included: nasopharyngitis, upper respiratory tract infection, injection site erythema, headache, arthralgia, pruritus and back pain. The types of adverse events reported remained generally consistent through 48 weeks of treatment.5,5


Guselkumab is an injectable treatment for psoriasis and can be self-administered following training. Treatment requires two starter doses, one initially and the other four weeks later, followed by a maintenance dose once every eight weeks (q8w) thereafter.7,8,8

Editor's Details

Mike Wood

Last updated on: 23/11/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.